ZETA SURGICAL® Achieves FDA Clearance for Enhanced Neurosurgical Solutions

ZETA SURGICAL® Achieves FDA 510(k) Clearance for Neurosurgical Instruments

On May 1, 2026, ZETA SURGICAL® celebrated a significant milestone as it announced the clearance of its Zeta Navigation System and its associated tools, the Zeta Stylet and Zeta Bolt, by the U.S. Food and Drug Administration (FDA). This advancement is expected to expand access to critical neurosurgical procedures, notably brain tumor biopsies, hydrocephalus treatment, and trigeminal neuralgia interventions.

The Zeta Navigation System is classified as a Class II stereotaxic instrument under product code HAW. This innovative system utilizes computer vision and artificial intelligence to enhance the precision of neurosurgical practices. By aligning preoperative CT or MRI scans with the patient’s anatomy in real-time, the system allows surgeons to navigate with millimeter-level accuracy across various points of care.

Dr. William Gormley, a co-founder of ZETA SURGICAL and Director of Neurosurgical Innovation at Harvard Medical School’s Brigham and Women’s Hospital, expressed enthusiasm over the recent approval: “Our mission has always been to democratize high-quality neurosurgical care for all patients, independent of treatment site. The FDA has taken a crucial step in this mission by approving our latest instruments designed for intricate neurosurgical procedures.”

The newly approved instruments offer navigational guidance that can significantly benefit common neurosurgical interventions, aiding in the placement of catheters for hydrocephalus and facilitating brain biopsies and trigeminal rhizotomies. Many of these interventions have historically encountered limitations regarding neuronavigation support, impacting the care of millions globally suffering from traumatic brain injuries or brain tumors.

Hieu Le Mau, the Chief Operating Officer at ZETA SURGICAL, emphasized the importance of integrating these instruments with the Zeta system, stating, “This approval is a tremendous addition to our surgical portfolio. It gives surgeons increased precision and confidence in performing diverse neurosurgical procedures, from external ventricular drains to biopsies and shunt placements.”

Previous trials have demonstrated promising outcomes for the Zeta system. In a recent study involving 15 patients, the use of the Zeta Navigation System for ventriculostomies yielded ideal placements in all cases, with a median setup time of less than three minutes. Following these successful trials, ZETA SURGICAL is gearing up for a large-scale commercial pilot program in collaboration with the Big 10 Neurosurgical Consortium within the year.

As they look to the future, ZETA SURGICAL is dedicated to improving surgical standards worldwide. The Zeta Navigation System is already cleared for use in the U.S. and aims to make advanced neurosurgical procedures accessible even in community hospitals and surgical centers globally.

For more information, you can visit ZETA SURGICAL's official website.